NuvOx Therapeutics, a clinical-stage biopharmaceutical company developing oxygen therapeutics for conditions driven by hypoxia, filed for an initial public offering. The company plans to list its common stock on the NYSE American under the symbol “NUOX.” It is offering 2,860,000 shares at an anticipated price range of $6.00 to $8.00 per share, with ThinkEquity as representative of the underwriters.

Business Description

NuvOx Therapeutics is a clinical-stage biopharmaceutical company developing NanO2, an intravenously administered oxygen therapeutic designed to address tissue hypoxia—a key driver of damage or treatment resistance in conditions such as acute ischemic stroke, glioblastoma multiforme (GBM), and acute respiratory distress syndrome (ARDS). NanO2’s active ingredient, dodecafluoropentane, is formulated as a nanoemulsion that transitions to a gas phase at body temperature, enabling high oxygen-carrying capacity and rapid diffusion into hypoxic tissues. Because NanO2’s particles are much smaller than red blood cells, they can partition into tissue and facilitate oxygen transfer from blood to where it is most needed.

The company has completed Phase Ib/IIa trials in stroke and GBM, has Orphan Drug Designation for GBM and sickle cell disease, and Fast Track designation for stroke. Its Phase IIb GBM study in the U.S. has completed enrollment (93 patients) and is in follow-up, a U.K. investigator-initiated Phase IIb stroke trial is underway, and a Canadian Phase Ib respiratory distress study has shown encouraging oxygenation improvements with dose escalation and is expected to be followed by a Phase II ARDS trial. NuvOx manufactures clinical supply in an ISO 7/ISO 5 cleanroom and holds an intellectual property estate that includes 11 issued U.S. patents and 31 foreign equivalents.

Market Overview

  • Total addressable market: GBM market was $2.5B in 2022 and is expected to reach $6.0B by 2032 (Emergen Research).
  • Market growth: U.S. stroke diagnostics and therapeutics projected to grow from $5.4B in 2023 to $11.6B by 2032 (CAGR ~8.9%).
  • Market growth: U.S. ARDS market projected to rise from $3.2B in 2021 to $7.1B by 2029 (CAGR ~10.6%).
  • Market position: No approved pharmaceutical treatments directly targeting tissue hypoxia in acute ischemic stroke, GBM or ARDS; NuvOx holds ODD in GBM and sickle cell, and Fast Track in stroke.
  • Key competitors: Stroke—NoNO (nerinetide), ZZ Biotech, GNT Pharma, Edaravone, Prolong Pharma; GBM radiosensitizers—valproic acid, chloroquine, Shuttle Pharmaceuticals, EpicentRx; ARDS—Direct Biologics, Veru, Vasomune, Aqualung.
  • Industry trends: Focus on neuroprotection, oxygen delivery technologies, and ICU burden reduction for respiratory failure.

Operational Metrics

  • Customers: Not applicable; company is pre-commercial
  • Locations: Headquarters and ISO 7/ISO 5 cleanroom manufacturing facility in Tucson, Arizona
  • Geographic presence: Clinical activity in the U.S., U.K., and Canada
  • Partnerships: Non-dilutive funding and collaborations with NIH, DoD, BARDA, and NIHR (U.K.), plus university and hospital trial sites
  • Clinical progress (GBM): Phase IIb U.S. trial fully enrolled with 93 patients; follow-up ongoing
  • Clinical progress (Stroke): U.K. Phase IIb investigator-initiated trial under way, 17 patients treated to date
  • Clinical progress (ARDS): Canadian Phase Ib (dose escalation) completed two cohorts with 12 patients; positive preliminary oxygenation signals
  • Manufacturing: In-house GMP-oriented clinical production; plan to tech transfer/duplicate at a CMO ahead of pivotal trials
  • Intellectual property: 11 U.S. patents and 31 foreign equivalents; ODD in GBM and sickle cell; Fast Track in stroke
  • Funding to date: $21.4M private financing; $10.8M non-dilutive grants received; $1.7M additional grants awarded but not yet received; $2.0M grants awarded to collaborators

Financials Highlights

  • Revenue (current): FY2025: $0.98M (grants and services); Q1 2026: $0.24M
  • Revenue growth: FY2025 revenue up ~91% vs. FY2024
  • Operating income: Loss from operations (FY2025): $(5.10)M
  • Net income: Net loss (FY2025): $(16.59)M; Net loss (Q1 2026): $(6.85)M

Management

  • Evan Unger, M.D., Executive Chairman - Radiologist, serial biotech founder (ImaRx Pharmaceutical/ Therapeutics), over 120 issued U.S. patents; led teams developing multiple FDA-approved drugs.
  • Rong Wang, President and Chief Executive Officer - More than 20 years in finance and operations; prior roles at Baxter, Ekso Bionics, and Abaxis; MBA (Michigan), CFA.
  • Jennifer L. H. Johnson, Ph.D., Chief Operating Officer - 20+ years in pharma development and regulatory; prior roles at Roche/Ventana and Microbion; Ph.D. in Pharmaceutical Science.
  • Richard Carmona, M.D., Director - 17th Surgeon General of the United States; academic and clinical leadership across medicine, public health, and preparedness.
  • Marvin J. Slepian, M.D., J.D., Director - Regents’ Professor at University of Arizona; prolific inventor and entrepreneur in cardiovascular devices and biomaterials.
  • Jon S. Saxe, J.D., LL.M., Director - Former President, PDL BioPharma; senior leadership and board roles across numerous biotech companies.

IPO Structure

  • Issuer: NuvOx Therapeutics, Inc.
  • Filing date: July 17, 2026
  • Proposed ticker: NUOX
  • Exchange: NYSE American
  • Price range: $6.00–$8.00
  • Offering size: 2,860,000 shares (45-day 429,000-share over-allotment)
  • Shares offered: 2,860,000 shares (plus 429,000-share over-allotment option)
  • Lead underwriters: ThinkEquity (representative)
  • Use of proceeds: Approx. $5.0M to complete Phase IIb GBM trial; $0.5M for stroke trial supply; $0.5M to complete Phase Ib ARDS trial; $1.0M to prepare Phase III GBM; ~$6.0M to fund Phase II ARDS; remainder for development and working capital.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.